China Approves First PD-1 Treatment: Bristol-Myer Squibb's Opdivo

The China National Drug Administration (CNDA) has approved Opdivo, the first PD-1 drug approved in China . A Bristol-Myers Squibb drug, Opdivo is approved as a second-line treatment for advanced or metastatic non-small cell lung cancer following platinum-based chemotherapy in adults. Opdivo improved survival rate over chemotherapy by 32% in a Phase III trial in which 90% of the patients were from China . The trial was stopped early because of Opdivo's efficacy. More details.... Stock Symbol: (NYSE: BMY) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.